Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD), an inherited retinal disease.
Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss.
Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space.
The Company is supported by funds from Syncona, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors.
Company Details
- Employees
- 91
- Founded
- -
- Address
- 14193 Nw 119th Terrace,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.beacontx.com/
- HQ
- Alachua, Florida
Beacon Therapeutics Questions
Beacon Therapeutics's website is https://www.beacontx.com/
Beacon Therapeutics's LinkedIn profile is https://www.linkedin.com/company/beacon-therapeutics
Beacon Therapeutics has
91 employees.
View email and phone details for 91
employees at Beacon Therapeutics.
Beacon Therapeutics's industry is
Biotechnology Research
Beacon Therapeutics's top competitors are
Atsena Therapeutics,
4d Molecular Therapeutics,
Ray Therapeutics, Inc.,
Ascend Advanced Therapies,
Agtc,
Nanoscope Therapeutics Inc.,
Syncona Limited,
Aavantgarde,
Cartesian Therapeutics,
Ocugen.
Beacon Therapeutics's categories are Biotechnology Research
Beacon Therapeutics's founding year is 2023
